[ET Net News Agency, 27 July 2026] Nomura lowered the target price for Hengrui Pharma (01276) to HKD82.18 from HKD87.49 and maintained the "buy" rating.
The research house said it lowers FY26F revenue/earnings estimates by 7.8%/18.4%, to reflect a slower-than-expected pace of out-licensing revenue recognition. (rc)
The research house said it lowers FY26F revenue/earnings estimates by 7.8%/18.4%, to reflect a slower-than-expected pace of out-licensing revenue recognition. (rc)